TriangleCapecitabine (NCT03161522)
Capecitabine trial for Gastric Adenocarcinoma (NCT03161522). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people older than eighteen and under eighty with esophageal or gastric adenocarcinoma and at most three metastatic lesions. Cancer must not progress during initial study chemotherapy before randomization.
The idea: after six to eight chemotherapy cycles, compare maintenance chemotherapy against chemotherapy plus local radiation, with surgery when appropriate. Chemotherapy interferes with cancer-cell growth; radiation targets cancer with high-energy rays. Surgery is not required for everyone. Researchers compare survival, disease control and toxicity.
This phase 2 study plans 100 patients. Quynh-Nhu Nguyen leads MD Anderson's single recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.